VRTX
Vertex Pharmaceuticals Inc
$546.12-2.12%
Setup
Near pivot
Buy Zone
$560.25-$588.26
Sector
Biotechnology
Industry
Biotechnology
51
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
VRTX chart
Loading chart…
ADX
Developing29.8Long Term
Up ↑Intermediate Term
Up ↑Short Term
Range →Overall Quality51
RS Rating
71
relative strength
Fundamentals
62
Solid fund-Q
Volume Demand
45
-46% vs avg
Technical Setup
88
7/8 checks
Industry/Theme
91
Biotechnology
Trade Plan
Avoid
Entry
$560.25
Entry Zone
$560.25-$588.26
Stop / Risk
$515.43
RS Rating
71
Volume confirmed
No
Targets
$672.3 / $700.31
Breakout · IBD Setup
5 ✓ 3 ✗
Entry $560.25–$588.26Stop $515.43Target $672.3 / $700.31
Market regimeUptrend
Quality51
RS Rating71
Above 50-MA+7.34%
Above 200-MA+17.16%
VolumeWeak
In Buy ZoneYes
Not extendedOK
Invalidation · Close below stop
How this came together
51
MarketUptrend
SetupNear pivot
ConfidenceExperimental · not backtested
Fund-Q62 · Solid
StatusAvoid
Stock Data
52-Week Range374 – 560
Price % Chg YTD20.46%
Price % Chg 4wk12.83%
50-Day Avg Vol1.5 Mil
P/E Ratio31.8
Market Cap$138B
SectorHealthcare
IndustryBiotechnology
Company Fundamentals
EPS % Chg (Qtr)8.02%
Sales % Chg (Qtr)11.99%
EPS Growth 5y8.28%
Sales Growth 5y14.23%
Annual ROE23.54%
Gross Margin86.12%
Operating Margin39.54%
Net Margin34.69%
Debt / Equity0.10
Setup levels
Current price
$546.12
Pivot
$560.25
Distance to buy
-2.5%
52-week range
374.16-560.24
Trigger evidence
No active trigger evidence available.
Pattern levels: pivot 560.25
Financial health checks
5/5
Return on equity above 15%
ROE 23.54%
Net margin above 10%
Net margin 34.69%
EPS growing quarter on quarter
EPS q/q 8.02%
Sales growing quarter on quarter
Sales q/q 11.99%
Debt to equity below 1.0
D/E 0.10
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE23.54%
vs sector +1.4%
Net margin34.69%
vs sector +17.7%
Gross margin86.12%
vs sector +19.5%
EPS growth q/q8.02%
vs sector +0.0%
Sales growth q/q11.99%
vs sector -6.5%
Debt / equity0.10
vs sector -0.54
Business quality
62
GradeSolid
EPS rating38
P/E31.8
Market cap$138B
IndustryBiotechnology
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Pass
Volumen bestätigt
Fail
In Kaufzone
Pass
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-09-01
Trigger date
—
Days on list
6
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.